Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Mosaic Immunoengineering Inc
(OP:
CPMV
)
0.8988
-0.1012 (-10.12%)
Streaming Delayed Price
Updated: 1:53 PM EDT, Sep 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Mosaic Immunoengineering Inc
Mosaic ImmunoEngineering Agrees to Acquire Clinical Necroptosis Cancer Therapy Assets from Oncotelic Therapeutics, Inc.
April 29, 2024
Via
ACCESSWIRE
Mosaic ImmunoEngineering Announces Issuance of U.S. Patent Covering Cancer Treatment with Its Lead Immuno-Oncology Candidate MIE-101
April 11, 2023
Via
ACCESSWIRE
UPDATE: Mosaic ImmunoEngineering's Academic Collaborators Awarded Grants Totaling $4.3 Million from NCI Focused on the Company's Novel Immuno-Oncology Platform
October 31, 2022
Via
ACCESSWIRE
Mosaic ImmunoEngineering’s Academic Collaborators Awarded Grants Totaling $4.3 Million from NCI Focused on the Company’s Novel Immuno-Oncology Plat-form
October 31, 2022
Via
ACCESSWIRE
Mosaic ImmunoEngineering Announces Completion of Exclusive Technology License Agreement with Case Western Reserve University
May 05, 2022
Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.
From
Mosaic ImmunoEngineering Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Newly Published Data Further Support Mosaic ImmunoEngineering’s Lead Immuno-Oncology Candidate MIE-101 in Combination with OX40 Checkpoint Treatment in Melanoma
February 02, 2022
- Broad, durable, and systemic anti-tumor immunity observed using inCPMV with OX40 agonist antibodies - Intratumoral inCPMV administration in combination with systemic anti-OX40 controlled the...
From
Mosaic ImmunoEngineering Inc.
Via
AccessWire
Mosaic ImmunoEngineering's Lead Immuno-Oncology Candidate MIE-101 Highlighted in Keynote Presentation
November 01, 2021
- Nanoparticle technology shown to be effective in transforming immunologically "cold" tumors to "hot" - - Data presented support durable antitumor activity - NOVATO, CA / ACCESSWIRE / November 1, 2021...
From
Mosaic ImmunoEngineering Inc.
Via
AccessWire
Exposures
COVID-19
Mosaic ImmunoEngineering Announces Upcoming Presentation at the 23rd Annual SoCalBio Conference
October 20, 2021
Presentation to highlight Mosaic's naturally-derived immuno-oncology candidate, MIE-101 Intratumoral administration of MIE-101 activates immune cells to initiate potent, systemic and durable antitumor...
From
Mosaic ImmunoEngineering Inc.
Via
AccessWire
Exposures
COVID-19
Spotlight Presentation at the World Molecular Imaging Congress Highlights Mosaic ImmunoEngineering's Immuno-Oncology and Modular Vaccine Platform Candidates
October 12, 2021
- Presentation detailed the Company's COVID-19 vaccine candidates that generated antibodies that neutralized SARS-CoV-2 infection of human cells - Vaccine candidates hold potential for rapid response...
From
Mosaic ImmunoEngineering Inc.
Via
AccessWire
Exposures
COVID-19
Mosaic ImmunoEngineering Expands Immuno-Oncology Platform Through New Technology Licensing Agreement with the University of California San Diego
October 06, 2021
- Nanoparticle-based technology complements the company's intratumoral technology platform - NOVATO, CA / ACCESSWIRE / October 6, 2021 / Mosaic ImmunoEngineering, Inc. ("Mosaic" or the "Company"),...
From
Mosaic ImmunoEngineering Inc.
Via
AccessWire
Exposures
COVID-19
Upcoming Presentation at the World Molecular Imaging Congress to Highlight Mosaic ImmunoEngineering’s Lead Immuno-Oncology and Modular Vaccine Platform COVID-19 Vaccine Candidates
October 01, 2021
NOVATO, CA / ACCESSWIRE / October 1, 2021 / Mosaic ImmunoEngineering Inc. ("Mosaic" or the "Company"), (OTCQB:CPMV), a development-stage biotechnology company focused on bridging immunology and...
From
Mosaic ImmunoEngineering Inc.
Via
AccessWire
Exposures
COVID-19
Mosaic ImmunoEngineering Announces Keynote Presentation Highlighting its Modular Vaccine Platform Delivery Technology
September 27, 2021
- Presentation highlighted potential of polymer-based delivery system for slow-release of vaccines that potentially require no booster shots - - Delivery system is transportation and storage friendly...
From
Mosaic ImmunoEngineering Inc.
Via
AccessWire
Exposures
COVID-19
Mosaic ImmunoEngineering Announces Publication of Data Supporting the Potential of Its SARS-CoV-2 Vaccine Candidates under its Modular Vaccine Platform
September 23, 2021
Vaccine candidates triggered high production of neutralizing antibodies against SARS-CoV-2 and SARS-CoV-1 in preclinical studies Epitopes used in the vaccine candidates are located in regions that are...
From
Mosaic ImmunoEngineering Inc.
Via
AccessWire
Exposures
COVID-19
Mosaic ImmunoEngineering Expands Its Modular Vaccine Platform (MVP) Through New Technology Licensing Agreement with the University of California San Diego
September 21, 2021
- Licensed Candidates Hold Potential to Address Emerging SARS-CoV-2 and other Infectious Diseases Including Human and Veterinary Applications - - Data Supporting the Potential of Lead Vaccine...
From
Mosaic ImmunoEngineering Inc.
Via
AccessWire
Exposures
COVID-19
Newly Published Preclinical Data Highlight Broad Immune Activation of Mosaic ImmunoEngineering’s Lead Intratumoral Immunotherapy Candidate, MIE-101
June 29, 2021
- Results Demonstrate Innate Immune System Activation Through Stimulation of Three Toll-Like Receptors (TLRs 2,4,7) - - MIE-101 Therapy Reduced Tumor Growth by 80% Compared to Tumors Treated with...
From
Mosaic ImmunoEngineering Inc.
Via
AccessWire
Exposures
COVID-19
Mosaic ImmunoEngineering Submits Application for Nasdaq Uplisting
June 28, 2021
NOVATO, CA / ACCESSWIRE / June 28, 2021 / Mosaic ImmunoEngineering Inc. ("Mosaic" or the "Company"), (OTCQB:CPMV), a development-stage biotechnology company focused onimmunotherapies to treat and...
From
Mosaic ImmunoEngineering Inc.
Via
AccessWire
Exposures
COVID-19
Mosaic ImmunoEngineering Inc. Elects Biotechnology Industry Veteran Robert A. Baffi, Ph.D. to Its Board of Directors
June 15, 2021
Experience in the Development of Biotechnology and Viral Based Therapeutics Will Help Enhance the Development of the Company's Pipeline NOVATO, CA / ACCESSWIRE / June 15, 2021 / Mosaic...
From
Mosaic ImmunoEngineering Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.